Morocco medicine price database

CINNORA

ADALIMUMAB

Active substance

ADALIMUMAB

Laboratory

PHARMIS

What is this medicine?

HADLIMA (adalimumab-bwwd) is a biosimilar to HUMIRA (adalimumab) that acts as a tumor necrosis factor (TNF) blocker.

Verified summary

ADALIMUMAB, SOLUTION INJECTABLE (S/C) EN SERINGUE PREREMPLIE, 40 MG / 0,8 ML, BOITE DE DEUX SERINGUES PREREMPLIES DE 0,8 ML

Common uses

moderately to severely active rheumatoid arthritis,moderately to severely active polyarticular juvenile idiopathic arthritis,active psoriatic arthritis,active ankylosing spondylitis,moderately to severely active Crohn’s disease,moderately to severely active ulcerative colitis,moderate to severe chronic plaque psoriasis,moderate to severe hidradenitis suppurativa,non-infectious intermediate, posterior, and panuveitis

Class

tumor necrosis factor (TNF) blocker

Laboratory

PHARMIS

Strength

40 MG / 0,8 ML

Form

SOLUTION INJECTABLE (S/C) EN SERINGUE PREREMPLIE

Presentation

BOITE DE DEUX SERINGUES PREREMPLIES DE 0,8 ML

Commercial status

Non commercialisé / Sans Prix

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-06-01: Not available in the verified source

Medicines with the same active substance